Myoclonus induced by salbutamol: A case report

María Alejandra Montoya-Giraldo, Dayana Vanessa Montoya, David Alexander Atehortúa, Jefferson Antonio Buendía, Andrés Felipe Zuluaga, .

Keywords: Myoclonus, albuterol, pharmacovigilance, drug-related side effects and adverse reactions, pharmacology, toxicology

Abstract

Salbutamol is a β2 adrenergic agonist widely prescribed in patients with obstructive and restrictive lung diseases. The main side effects associated with its use are tachycardia and tremor. Myoclonus is an involuntary, irregular, abrupt, brief and sudden muscular contraction, which can be generalized, focal or multifocal.
We report the case of a 61-year-old patient presenting with myoclonus difficult to treat who showed improvement only after the definitive discontinuation of the β2 adrenergic agonist. We describe the clinical findings, the interventions, and the outcomes related to the onset of myoclonus secondary to the use of salbutamol, as well as the possible genesis and importance of this adverse effect. We used the CARE guidelines to delineate the clinical case.
Although myoclonus secondary to the use of different drugs has been described in the literature, as far as we know this is the fourth report of salbutamol-induced myoclonus to date.

Downloads

Download data is not yet available.
  • María Alejandra Montoya-Giraldo Centro de Información y Estudio de Medicamentos y Tóxicos, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Dayana Vanessa Montoya Centro de Información y Estudio de Medicamentos y Tóxicos, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • David Alexander Atehortúa Centro de Información y Estudio de Medicamentos y Tóxicos, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Jefferson Antonio Buendía Centro de Información y Estudio de Medicamentos y Tóxicos, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Andrés Felipe Zuluaga Centro de Información y Estudio de Medicamentos y Tóxicos, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

References

Palmer E. Top 20 generic molecules worldwide: Fierce Pharma. Fecha de consulta: 30 de enero de 2018. Disponible en: https://www.fiercepharma.com/special-report/top-

-generic-molecules-worldwide

Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690-6. https://doi.org/10.1164/rccm.201209-1739PP

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: Consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2013-201554

Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: A practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4:47-62. https://doi.org/10.1177/1756285610395653

Fahn S, Marsden CD, van Woert MH. Definition and classification of myoclonus. Adv Neurol. 1986;43:1-5.

Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011;114:695-707. https://doi.org/10.1097/ALN.0b013e3181ff72b5

Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: Frequency, mechanisms and management. CNS Drugs. 2004;18:93-104.

Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Drug-induced myoclonus: A French pharmacovigilance database study. Neurophysiol Clin. 2006;36:333-6. https://doi.org/10.1016/j.neucli.2006.12.003

Pierce DA, Holt SR, Reeves-Daniel A. A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure. Clin Ther. 2008;30:1681-4. https://doi.org/10.1016/j.clinthera.2008.09.004

Mícheli F, Cersósimo MG, Scorticati MC, Vélez M, González S. Myoclonus secondary to albuterol (salbutamol) instillation. Neurology. 2000;54:2022-3.

Holloway K, Green T, World Health Organization. Drug and therapeutics committees: A practical guide. Ginebra: Organización Mundial de la Salud; 2003. p. 146.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. https://doi.org/10.1038/clpt.1981.154

Levy A, Chen R. Myoclonus: Pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18:21. https://doi.org/10.1007/s11940-016-0404-7

Toro C, Hallett M. Pathophysiology of myoclonic disorders. En: Movement disorders: Neurologic principles and practice. Tercera edición. Watts RL, Koller WC (editores) New York: McGraw-Hill; 2004.

Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: Treatment strategies. J Pain Symptom Manage. 1997;14:51-8. https://doi.org/10.1016/S0885-3924(97)00001-8

How to Cite
1.
Montoya-Giraldo MA, Montoya DV, Atehortúa DA, Buendía JA, Zuluaga AF. Myoclonus induced by salbutamol: A case report. biomedica [Internet]. 2018 Sep. 1 [cited 2024 May 18];38(3):303-7. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/3813

Some similar items:

Published
2018-09-01
Section
Case presentation

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code